Louie, Bryan H. http://orcid.org/0000-0001-6922-5396
Kato, Shumei
Kim, Ki Hwan
Lim, Hyo Jeong
Okamura, Ryosuke http://orcid.org/0000-0001-7352-8621
Eskander, Ramez N.
Botta, Gregory
Patel, Hitendra
Lee, Suzanna http://orcid.org/0000-0002-9502-4907
Lippman, Scott M.
Sicklick, Jason K. http://orcid.org/0000-0003-4403-0271
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NIH P30 CA023100)
Article History
Received: 16 May 2022
Accepted: 23 August 2022
First Online: 22 September 2022
Competing interests
: S.K. serves as a consultant for Foundation Medicine and receives speaker’s fees from Roche. G.B. has received speaker’s fees from and serves on the Advisory Board of Natera and has received institutional funding from Carsgen. R.N.E. reports personal fees for consulting/advisory and/or institutional support/grants for clinical research outside of the submitted work from AstraZeneca, Merck, GSK/Tesaro, Eisai, Myriad, Novocure, Immunogen, Mersana, Seagen, Clovis oncology, and GOG-Foundation and is an institutional PI for industry sponsored trials from Clovis, Genentech/Roche, Novocure, and AstraZeneca. S.M.L. is on the scientific advisory board for Biological Dynamics and co-founded io9. J.K.S. receives research funds from Foundation Medicine Inc. and Amgen; consultant fees from Deciphera and Grand Rounds; speakers fees from Deciphera, La-Hoffman Roche, Foundation Medicine, Merck, and QED. R.K. has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, and Konica Minolta, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Genentech and NeoMed. She receives speaker fees from Roche, and has an equity interest in IDbyDNA and Curematch, Inc, and serves on the Board of CureMetrix and CureMatch. B.H.L., K.H.K., H.J.L., R.O., H.P., and S.L. have no competing interests.